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Aim: To study collagen-induced arthritis in human leucocyte antigen (HLA)-DR1 transgenic mice lacking
endogenous major histocompatibility complex class II molecules (MHC-II) and to determine T cell specificity
against the arthritogenic CII259–273 epitope of type II collagen either unmodified or post-translationally
glycosylated at Lys264.
Methods: Arthritis was induced by immunisation with human type II collagen in complete Freund’s adjuvant
and measured by footpad swelling, clinical score and histology. T cell responses were assessed by
proliferation of spleen and lymph node cells and in antigen presentation assays, using T cell hybridomas
specific for the glycosylated and non-glycosylated CII259–273 epitope.
Results: The incidence of arthritis was 50% in DR1-transgenic mice lacking endogenous MHC-II molecules.
Recall T cell responses in draining lymph nodes and spleen were consistently greater against the non-
glycosylated epitope than to the glycosylated CII259–273. Most of the T cell hybridomas generated from CII-
immunised mice recognised the non-glycosylated CII epitope and this form of the epitope was also presented
with 100-fold higher efficiency and 1 h faster kinetics by both macrophages and dendritic cells.
Conclusion: This study shows that T cell responses to the non-glycosylated epitope of heterologous (human) CII
are dominant in HLA-DR1 transgenic mice lacking MHC-II, which could contribute to the pathogenicity of
autoimmune arthritis.
T
he contribution of human leucocyte antigen (HLA)-DRB1
alleles to the pathogenesis of rheumatoid arthritis (RA) is
estimated as 40%.1 In particular, the expression of HLA-
DR4 (HLA-DRB1*0401) and HLA-DR1 (HLA-DRB1*0101) has
been shown to predispose to RA.2–5 HLA-DRB1*0401 is
associated with severe erosive RA, whereas expression of
HLA-DRB1*0101 is associated with less severe non-erosive
disease.5–7
The primary structure of the peptide-binding pocket of
mouse major histocompatibility complex class II (MHC-II) Aq
molecules has been shown to be very similar to that of HLA-
DRB1*0401 and HLA-DRB1*01018 and expression of Aq confers
susceptibility to collagen-induced arthritis (CIA).9 10 Mice
expressing non-susceptible MHC haplotypes (ie, not H-2q or
H-2r11) that express HLA-DRB1*0401 or HLA-DRB1*0101 also
acquire susceptibility to CIA12–14 but it is not known whether the
endogenous mouse MHC class molecules contribute in anyway
to the induction or severity of arthritis.
T cells from type II collagen (CII)-immunised HLA-
DRB1*0401 and HLA-DRB1*0101 mice predominantly recognise
the same immunodominant CII259–273 epitope.
11–13 15 16 In HLA-
DRB1*0401 CD4 double transgenic mice lacking MHC-II, the T
cells recognised many different forms of the peptides including
the glycosylation of the Lys264 residue within the CII259–273
epitope.17–19 Interestingly, when these mice expressed huma-
nised CII the response to the glycosylated structure was
relatively stronger indicating a less well-developed tolerance
to post-translationally modified CII epitopes.14 17
METHODS
Antigens
Human CII was purchased from MD BioSciences (Zu¨rich,
Switzerland). The glycosylated peptide (GIAGFKGEQGPKGET;
K = GalHyL264) corresponding to epitope CII259–273 was
synthesised.20 The non-glycosylated peptide pCII259–273 was
purchased from GenScript Corp (Piscataway, New Jersey,
USA).
Animals
Transgenic (tg) mice carried full-length genomic constructs for
HLA-DRA1*0101 and HLA-DRB1*010121 and were crossed for
more than six generations to C57BL/6 Ab null mice.22 Breeding
founders were genotyped by PCR for the presence of the HLA
transgenes and HLA-DR expression was monitored by flow
cytometry.23 24 The proportion of T cells, B cells, macrophages
and dendritic cells as well as the level of expression of MHC II
molecules (HLA-DR1 compared with Ab) and T cell receptor
(TCR) Vb family distribution were comparable between HLA-
DR1-tg mice and C57BL/6, the background mouse strain (data
not shown). The work was approved by the ethics committee of
the Newcastle University.
Collagen-induced arthrit is
CIA was induced by immunisation at the base of the tail with
100 mg human CII in complete Freund’s adjuvant (CFA,
Chondrex, Washington, USA). The same dose of CII in
incomplete Freund’s adjuvant (IFA) was given 3 weeks later.
The severity of CIA was monitored as the thickness of the hind
paws using an Oditest dial caliper gauge (reading error of
0.01 mm, Kroeplin GmbH, Schu¨chtern, Germany). Clinical
scoring was performed using an established scoring system:
0 = normal joints, 1 = 1 or 2 swollen joints, 2 =.2 swollen
Abbreviations: APC, antigen presenting cells; CFA, complete Freund’s
adjuvant; CIA, collagen-induced arthritis; DC, dendritic cells; FITC,
fluorescein isothiocyanate; HLA, human leucocyte antigen; IFA, incomplete
Freund’s adjuvant; MHC-II, major histocompatibility complex class-II; PBS,
phosphate-buffered saline; PE, phycoerythrin; RA, rheumatoid arthritis;
TCR, T cell receptor; TG, transgenic
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joints and 3 = extreme swelling of the entire paw and/or
ankylosis.12
Cells
Culture media ingredients were from Sigma Chemical Co
(Dorset, UK). Cells were grown in culture medium (RPMI 1640
medium containing 3 mM L-glutamine, 50 mM 2-mercapto-
ethanol, 10% fetal bovine serum and 30 mg/ml gentamycin). T
cell hybridomas were generated by polyethylene–glycol fusion
of BW5147 (TCRa-b-) cells with T cell lines from CII-immunised
mice after six rounds of restimulation. Macrophages (purity
,95% based on CD11b expression) were grown from femoral
bone marrow cells in culture medium containing L929 super-
natant as a source of macrophage colony stimulating factor (M-
CSF).23 Macrophages were activated with 10 U/ml recombinant
IFNc (R&D Systems, Abingdon, UK) for 24 h.23 Bone marrow
dendritic cells (DC, purity ,92% based on CD11c expression)
were grown in culture medium containing 20 ng/ml recombi-
nant mouse granulocyte–macrophage colony stimulating factor
(GM-CSF, BioSource International, Nivelles, Belgium). DC
were purified using anti-CD11c-coated magnetic microbeads
(Miltenyi Biotec, Bisley, UK) and maturation was induced by
0.2 mg/ml lipopolysaccharide for 24 h.24
Proliferation assays
CII-specific T cell proliferation responses were measured in
popliteal lymph nodes removed 7 days after immunisation with
50 mg CII emulsified 1:1 in TiterMax adjuvant (Sigma Chemical
Co) or phosphate-buffered saline (PBS)/TiterMax. Responses of
spleen cells were measured in mice with CIA. Cells (26105/
well) were mixed with antigens or the polyclonal T cell mitogen
concanavalin A (5.0 mg/ml) and incubated for 4 days, including
14.8 kBq of [3H]-thymidine for the past 18 h and radioactivity
was measured as described below.
Antigen presentation assays
Adherent macrophages at 105/well or DC at 104/well were
pulsed with a dilution series of CII or synthetic peptides, fixed
with 1.0% paraformaldehyde, and T cell hybridoma HCII-9.1
((CD3+ TCRab+ Vb14+) specific for the non-glycosylated
peptide) or HCII-9.2 ((CD3+ TCRab+ Vb8.1/8.2+) specific for
the glycosylated peptide) were added (56104/well) and
incubated for 24 h at 37 C˚.23 Responses to synthetic peptides
were used as a positive control for T cell hybridomas. The
interleukin (IL)2 content of hybridoma supernatants was
measured as proliferation of the cytotoxic T cell line 2 (CTLL-
2, 36104/well, American Type Culture Collection ATCC, TIB
214, Rockville, Maryland, USA) incubated for 18 h in the
presence of 14.8 kBq of [3H]thymidine (TRA310, specific
activity 307 MBq/mg; Amersham International plc, Didcot,
UK). Cells were harvested on glass fibre membranes and
radioactivity was quantitated using a direct beta counter
(Matrix 9600, Packard Instrument Company, Meridan,
Connecticut, USA). To measure non-specific, polyclonal
responses of T cell hybridomas, a dilution series of rat anti-
CD3 antibodies (clone KT3, generous gift of Dr CG Brooks,
Newcastle University) were coated on 96 well plates, and T cell
hybridoma were added and assayed as above.
Histology
Arthritic and non-arthritic paws were removed and fixed in 7%
formaldehyde pH 7.4, decalcified in 14% EDTA pH 7.4, and
embedded in paraffin wax. Serial sections (5 mm) of the joints
were stained with H&E and examined as blinded samples at the
Department of Cellular Pathology, Royal Victoria Infirmary,
Newcastle upon Tyne, UK.
Flow cytometry
Cells were incubated for 30 min at 4 C˚ in Hank’s balanced salt
solution containing 2% fetal bovine serum, 0.01 M
N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid with
purified anti-mouse CD16/CD32 (Fc Block, BD-PharMingen,
Oxford, UK) followed by incubation for 30 min at 4 C˚ with
either of the following mAb fluorescent conjugates (BD-
PharMingen) specific for: TCRab/phycoerythrin (PE), HLA-
DR/fluorescein isothiocyanate (FITC) or HLA-DR/PE, CD11c/
FITC, CD11b/FITC, CD19/PE, CD4/FITC, CD8/FITC, I-Ab/FITC or
rat IgG2a/PE plus IgG2b/FITC as isotype controls. The TCR Vb
family distribution in the spleen was studied using a panel of
FITC-conjugated mAb to mouse TCR Vb chains (BD-
PharMingen).25 Cells were analysed with by flow cytometry
(Becton Dickinson FACScan, Mount View, California, USA)
and 10 000 events were collected and analysed for each sample
using CellQuestPro software.
Statistical analysis
Statistical differences were analysed by two-way analysis of
variance and two-tailed paired t tests. Analysis of variance
Bonferroni post-tests were used to compare replicate means. The
dose of CII that induced 50% T cell hybridoma responses
(Effective dose50, ED50) was calculated according to the sigmoidal
or bottom-to-top curve fitting models (Prism 4.03 and GraphPad
StatMate 1.00, GraphPad Software Inc, San Diego, USA).
RESULTS
Development of collagen-induced arthritis
We induced CIA in HLA-DR1-tg mice lacking MHC-II by a
single subcutaneous immunisation with 100 mg CII emulsified
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Figure 1 Clinical scoring of
collagen-induced arthritis (CIA). CIA
was induced by single immunisation
with type II collagen (CII)/ complete
Freund’s adjuvant (CFA; filled
squares) or followed by a second
immunisation with CII/IFA 3 weeks
later (filled circles). Mice received
phosphate-buffered saline/CFA as a
negative control (empty squares).
Hind paw thickness (A), clinical score
(B) and incidence of arthritis (C) were
measured. Data shown as mean and
SEM of 12 mice per group. PBS,
phosphate-buffered saline.
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in CFA. In some experiments CII/CFA immunisation was
followed by boosting with CII/IFA. Arthritis was observed
30 days after immunisation independently of the immunisation
protocol, evidenced by the increase in hind paw thickness and
clinical score compared with mice immunised with PBS/CFA
(fig 1A,B). The severity of arthritis peaked 45 days after
immunisation (fig 1A,B) corresponding to the maximum
incidence of 50% (fig 1C).
Macroscopically both hind and fore paws developed oedema
and redness with pronounced loss of function compared with
PBS/CFA-immunised mice (fig 2). Histological examination
revealed cartilage loss, synovial inflammation and bone
destruction of all small joints inspected from representative
hind-paws of three mice with CIA compared with control mice
(fig 2). The data showed that mice were susceptible to CIA with
clinical and histological features characteristic of RA.
Specificity of T cell responses
We studied the effect of CII259–273 glycosylation on T cell
specificity after CII/CFA immunisation. Sixty days after CII/CFA
immunisation, CII-specific spleen T cell responses were
detected only in arthritic mice (fig 3A,B). These T cell responses
showed a bias towards specificity for the non-glycosylated, as
compared with the glycosylated, CII259–273 epitope (p,0.001;
A CII/CFA immunised B Untreated mice
Fore paw
Hind paw
Histology
2
3
1
Figure 2 Appearance of collagen-induced
arthritis (CIA). Mice with CIA (A) but not
untreated mice (B) displayed extensive rubor
and oedema around metacarpophalangeal
and interphalangeal joints (top two panels)
and metatarsophalangeal and
interphalangeal joints (middle two panels).
H&E-stained sections are shown in the
bottom two panels, highlighting synovial
hyperplasia and inflammation (1), cartilage
destruction (2), and bone resorption with
pannus formation (3). Magnification 6400.
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fig 3A). Mice were also foot-pad immunised with CII/TiterMax
before popliteal lymph node assays 7 days later. T cell
proliferation was again biased to recognition of the non-
glycosylated epitope in addition to a response to intact CII
(p,0.001; fig 3C).
Specificity of T cell hybridoma responses
We generated a panel of 44 CII-specific T cell hybridomas from
six mice and assayed responses to the glycosylated and non-
glycosylated CII259–273 in an antigen presentation assay. Most
CII-specific T cell hybridomas (42/44, 95.5%) recognised the
non-glycosylated CII259–273 epitope, and only two T cell
hybridomas recognised the glycosylated epitope (fig 3D).
Altogether, our data showed that immunisation of HLA-DR1-
tg mice resulted in a predominant response to the non-
glycosylated CII259–273 epitope.
We addressed whether differences in processing and pre-
sentation of CII in professional antigen presenting cells (APCs)
accounted for the observed expansion of CD4 T cells specific for
the non-glycosylated CII259–273 epitope. We assayed antigen
presentation of the glycosylated and non-glycosylated CII259–273
epitope from soluble CII by DC and macrophages using two T
cell hybridomas with similar TCR affinities judged from dose-
response titrations to synthetic peptides and anti-CD3 anti-
bodies (fig 4), and levels of TCR expression by flow cytometry
(data not shown). The requirement for proteolytic processing
of soluble CII for presentation of the glycosylated and
non-glycosylated CII259–273 was reported previously.
23
Presentation of the glycosylated, as compared with the non-
glycosylated epitope, was characterised by significantly lower
efficiency in both macrophages (100-fold difference) and DC
(200-fold difference; fig 5A,B). Similarly, significantly delayed
kinetics (by approximately 1 h) of antigen presentation was
characteristic of the glycosylated, as compared with the non-
glycosylated epitope, in macrophages and in DC (fig 5C,D). The
data showed that CII was more efficiently processed by
professional APCs for presentation of the non-glycosylated,
compared with the glycosylated epitope. This apparent immu-
nodominance of the non-glycosylated CII259–273 in antigen
presentation experiments in vitro is consistent with expansion
of polyclonal T cells against this form of the epitope in HLA-
DR1-tg mice in vivo, shown in fig 3.
DISCUSSION
We studied the development of CIA after CII immunisation in
HLA-DR1-tg mice lacking MHC-II. In this study, a high severity
of CIA was observed with the incidence rate of approximately
50%. By contrast, HLA-DR1-tg(H2f) mice and HLA-DR4-tg mice
lacking MHC-II were reported to be highly susceptible to CIA
with 88–100% incidence rate.12 14 Previous population studies in
patients with RA showed that different HLA-DRB1 alleles
influence the severity of RA with HLA-DRB1*0401 being
associated with severe, seropositive, erosive RA, whereas
DRB1*0101 with less severe, seronegative, non-erosive
Figure 3 Type II collagen (CII)-specific T cell
responses. Proliferation responses of spleen
cells of mice immunised with CII/CFA with
arthritis (A) or without arthritis (B) to CII
(squares), non-glycosylated (circles) or
glycosylated (diamonds) peptides were
measured (C). Responses of popliteal lymph
node cells of mice foot-pad immunised with
CII/TiterMax (filled bars), or PBS/TiterMax
(empty bars) are shown as mean + SD of
three independent experimets and ‘‘*’’
indicates a significant difference between
responses to the glycosylated and non-
glycosylated epitope (p,0.001). (D) The
proportion of CII-specific T cell hybridomas
generated from six CII-immunised mice that
recognised CII and the glycosylated or non-
glycosylated peptides. Glyc pept,
glycosylated peptide; Non-glyc pept, non-
glycosylated peptide.
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disease.5–7 Further studies will shed light on the reasons for the
reduced incidence rate (but not the severity) of CIA in HLA-
DR1-tg mice lacking MHC-II.
CII-specific T cells in HLA-DR4-tg mice were shown to
recognise predominantly the non-glycosylated CII259-273, but
the response was skewed towards recognition of the glycosylated
form when the human CII was transgenically expressed.17–19 We
studied T cell responses in draining lymph nodes and spleen of
HLA-DR1-tg mice after CII immunisation and showed a bias
towards T cell responses specific for the non-glycosylated in
preference to the glycosylated CII259–273 epitope. This conclusion
was confirmed by producing a panel of CII-specific T cell
hybridomas, most of which recognised the non-glycosylated
epitope. We addressed whether the APC type determined the pre-
dominance of T cells specific for the non-glycosylated CII259–273
by studying antigen presentation of both forms of CII259–273 to T
cells by macrophages and DC, which have been previously shown
to be the major APC involved in CII presentation.23 26 27
Presentation of the glycosylated CII259–273 was characterised by
more than 100-fold lower efficiency and occurred with about 1 h
slower kinetics, as compared with the non-glycosylated epitope
independent of the APC type. Hence, high efficiency of antigen
presentation of the non-glycosylated CII259–273 could account for
the predominant specificity of peripheral T cells against the non-
glycosylated epitope. Low efficiency of antigen presentation of the
glycosylated CII259–273 could potentially reflect its lower affinity
for HLA-DR1, as glycosylation was shown previously to decrease
CII peptide affinity for Aq molecules.28
According to our unpublished data, adoptive transfer of the T
cell hybridoma HCII-9.1 specific for the non-glycosylated
CII259–273 epitope, but not the HCII-9.2 specific for the
glycosylated epitope, induced mild synovial inflammation in
small interphalangeal joints. Synovitis in small joints is
reported to be a reliable marker for subsequent x ray changes
in the same joints in RA,29 suggesting potential arthritogenicity
of the non-glycosylated form of CII259–273 in HLA-DR1-tg mice.
By contrast, arthritogenic T cell responses in HLA-DR4CD4-tg
mice lacking MHC-II had higher responses towards the
glycosylated CII259–273 epitope,
17 possibly due to the differential
processing of CII in HLA-DR1-tg and HLA-DR4/CD4-tg mice.
Our data suggest that post-translational glycosylation of Lys264
has different consequences for CII-specific T cell responses
restricted by different HLA-DRB1 alleles that confer suscept-
ibility to RA. We propose that HLA-DR1 biases response
towards the non-glycosylated epitope, as shown in the present
study. It remains to be determined whether the response will be
skewed towards recognition of the glycosylated peptide, as
observed in the DR4 mice, in a tolerising situation when human
CII is expressed.
Our finding is consistent with the presence of T cells specific
for both the glycosylated and non-glycosylated CII259–273 in
peripheral blood of patients with RA.17 30 Coexpression of both
HLA-DR1 and HLA-DR4 has been shown to increase the risk of
developing RA,5 which we propose could be due to the additive
effect of two HLA-DR susceptibility alleles presenting essen-
tially different forms of the CII259–273 epitope. Our study
suggests a pathophysiological role for HLA-DR1-restricted T cell
responses against a non-glycosylated CII epitope in murine CIA,
and shows that HLA-DR1-tg mice lacking MHC-II may be a
useful model to study the specificity of T cell responses in RA.
Figure 4 Dose-response titrations
of T cell hybridomas. Responses of T
cell hybridoma HCII-9.1 (closed
symbols, non-glycosylated epitope)
or HCII-9.2 (open symbols,
glycosylated epitope) to a dose
range of synthetic peptides (A) or to
anti-CD3 antibodies (B) are shown
as mean cpm (SD).
 
Figure 5 Antigen presentation. Macrophages (A) or DC (B) were pulsed
with CII for 5 h. Macrophages (C) or DC (D) were pulsed with CII for
different periods of time. Responses of T cell hybridoma HCII-9.1 (closed
symbols, non-glycosylated epitope) or HCII-9.2 (open symbols,
glycosylated epitope) are shown as mean cpm (SD) of a representative of
three experiments. Curve fitting was performed for EC50 calculations. Dose-
response EC50 values of the glycosylated and non-glycosylated epitope in
macrophages were 172.7 mg/ml and 1.4 mg/ml, respectively, and in DC
2.5 mg/ml and 0.01 mg/ml, respectively. Kinetics EC50 values of the
glycosylated and non-glycosylated epitope in macrophages were 4.9 h
and 3.6 h, respectively, and in DC by EC50 2.4 h and 1.5 h (1.0–1.9,
95% CI), respectively.
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